-
Je něco špatně v tomto záznamu ?
Cellular Delivery of Bioorthogonal Pretargeting Therapeutics in PSMA-Positive Prostate Cancer
S. Hapuarachchige, CT. Huang, MC. Donnelly, C. Bařinka, SE. Lupold, MG. Pomper, D. Artemov,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem, Research Support, U.S. Gov't, Non-P.H.S.
Grantová podpora
R01 CA209884
NCI NIH HHS - United States
- MeSH
- albuminy MeSH
- antigeny povrchové imunologie MeSH
- click chemie metody MeSH
- cyklooktany chemie MeSH
- fluorbenzeny chemie MeSH
- fytogenní protinádorové látky terapeutické užití MeSH
- glutamátkarboxypeptidasa II imunologie metabolismus MeSH
- imunoglobuliny - Fab fragmenty chemie metabolismus terapeutické užití MeSH
- lékové transportní systémy metody MeSH
- lidé MeSH
- maytansin terapeutické užití MeSH
- modulátory tubulinu terapeutické užití MeSH
- monoklonální protilátky chemie metabolismus terapeutické užití MeSH
- nádorové buněčné linie MeSH
- nádory prostaty farmakoterapie enzymologie metabolismus MeSH
- nanomedicína MeSH
- viabilita buněk účinky léků MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Research Support, N.I.H., Extramural MeSH
- Research Support, U.S. Gov't, Non-P.H.S. MeSH
Prostate cancer is primarily fatal after it becomes metastatic and castration-resistant despite novel combined hormonal and chemotherapeutic regimens. Hence, new therapeutic concepts and drug delivery strategies are urgently needed for the eradication of this devastating disease. Here we report the highly specific, in situ click chemistry driven pretargeted delivery of cytotoxic drug carriers to PSMA(+) prostate cancer cells. Anti-PSMA 5D3 mAb and its F(ab')2 fragments were functionalized with trans-cyclooctene (TCO), labeled with a fluorophore, and used as pretargeting components. Human serum albumin (ALB) was loaded with the DM1 antitubulin agent, functionalized with PEGylated tetrazine (PEG4-Tz), labeled with a fluorophore, and used as the drug delivery component. The internalization kinetics of components and the therapeutic efficacy of the pretargeted click therapy were studied in PSMA(+) PC3-PIP and PSMA(-) PC3-Flu control cells. The F(ab')2 fragments were internalized faster than 5D3 mAb in PSMA(+) PC3-PIP cells. In the two-component pretargeted imaging study, both components were colocalized in a perinuclear location of the cytoplasm of PC3-PIP cells. Better colocalization was achieved when 5D3 mAb was used as the pretargeting component. Consecutively, the in vitro cell viability study shows a significantly higher therapeutic effect of click therapy in PC3-PIP cells when 5D3 mAb was used for pretargeting, compared to its F(ab')2 derivative. 5D3 mAb has a longer lifetime on the cell surface, when compared to its F(ab')2 analogue, enabling efficient cross-linking with the drug delivery component and increased efficacy. Pretargeting and drug delivery components were cross-linked via multiple bioorthogonal click chemistry reactions on the surface of PSMA(+) PC cells forming nanoclusters, which undergo fast cellular internalization and intracellular transport to perinuclear locations.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20028615
- 003
- CZ-PrNML
- 005
- 20210114154447.0
- 007
- ta
- 008
- 210105s2020 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1021/acs.molpharmaceut.9b00788 $2 doi
- 035 __
- $a (PubMed)31840521
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Hapuarachchige, Sudath $u The Russell H. Morgan Department of Radiology and Radiological Science , The Johns Hopkins University School of Medicine , 720 Rutland Avenue , Baltimore , Maryland 21205 , United States.
- 245 10
- $a Cellular Delivery of Bioorthogonal Pretargeting Therapeutics in PSMA-Positive Prostate Cancer / $c S. Hapuarachchige, CT. Huang, MC. Donnelly, C. Bařinka, SE. Lupold, MG. Pomper, D. Artemov,
- 520 9_
- $a Prostate cancer is primarily fatal after it becomes metastatic and castration-resistant despite novel combined hormonal and chemotherapeutic regimens. Hence, new therapeutic concepts and drug delivery strategies are urgently needed for the eradication of this devastating disease. Here we report the highly specific, in situ click chemistry driven pretargeted delivery of cytotoxic drug carriers to PSMA(+) prostate cancer cells. Anti-PSMA 5D3 mAb and its F(ab')2 fragments were functionalized with trans-cyclooctene (TCO), labeled with a fluorophore, and used as pretargeting components. Human serum albumin (ALB) was loaded with the DM1 antitubulin agent, functionalized with PEGylated tetrazine (PEG4-Tz), labeled with a fluorophore, and used as the drug delivery component. The internalization kinetics of components and the therapeutic efficacy of the pretargeted click therapy were studied in PSMA(+) PC3-PIP and PSMA(-) PC3-Flu control cells. The F(ab')2 fragments were internalized faster than 5D3 mAb in PSMA(+) PC3-PIP cells. In the two-component pretargeted imaging study, both components were colocalized in a perinuclear location of the cytoplasm of PC3-PIP cells. Better colocalization was achieved when 5D3 mAb was used as the pretargeting component. Consecutively, the in vitro cell viability study shows a significantly higher therapeutic effect of click therapy in PC3-PIP cells when 5D3 mAb was used for pretargeting, compared to its F(ab')2 derivative. 5D3 mAb has a longer lifetime on the cell surface, when compared to its F(ab')2 analogue, enabling efficient cross-linking with the drug delivery component and increased efficacy. Pretargeting and drug delivery components were cross-linked via multiple bioorthogonal click chemistry reactions on the surface of PSMA(+) PC cells forming nanoclusters, which undergo fast cellular internalization and intracellular transport to perinuclear locations.
- 650 _2
- $a albuminy $7 D000418
- 650 _2
- $a monoklonální protilátky $x chemie $x metabolismus $x terapeutické užití $7 D000911
- 650 _2
- $a antigeny povrchové $x imunologie $7 D000954
- 650 _2
- $a fytogenní protinádorové látky $x terapeutické užití $7 D000972
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a viabilita buněk $x účinky léků $7 D002470
- 650 _2
- $a click chemie $x metody $7 D057930
- 650 _2
- $a cyklooktany $x chemie $7 D034242
- 650 _2
- $a lékové transportní systémy $x metody $7 D016503
- 650 _2
- $a fluorbenzeny $x chemie $7 D005464
- 650 _2
- $a glutamátkarboxypeptidasa II $x imunologie $x metabolismus $7 D043425
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunoglobuliny - Fab fragmenty $x chemie $x metabolismus $x terapeutické užití $7 D007140
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a maytansin $x terapeutické užití $7 D008453
- 650 _2
- $a nanomedicína $7 D050997
- 650 _2
- $a nádory prostaty $x farmakoterapie $x enzymologie $x metabolismus $7 D011471
- 650 _2
- $a modulátory tubulinu $x terapeutické užití $7 D050257
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a Research Support, N.I.H., Extramural $7 D052061
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a Research Support, U.S. Gov't, Non-P.H.S. $7 D013486
- 700 1_
- $a Huang, Colin T $u The Russell H. Morgan Department of Radiology and Radiological Science , The Johns Hopkins University School of Medicine , 720 Rutland Avenue , Baltimore , Maryland 21205 , United States.
- 700 1_
- $a Donnelly, Madeline C $u The Russell H. Morgan Department of Radiology and Radiological Science , The Johns Hopkins University School of Medicine , 720 Rutland Avenue , Baltimore , Maryland 21205 , United States.
- 700 1_
- $a Bařinka, Cyril $u Laboratory of Structural Biology , Institute of Biotechnology of the Czech Academy of Sciences , Prumyslova 595 , Vestec 252 50 , Czech Republic.
- 700 1_
- $a Lupold, Shawn E $u The James Buchanan Brady Urologic Institute and Department of Urology , Johns Hopkins School of Medicine , 600 N. Wolfe St. , Baltimore , Maryland 21287 , United States.
- 700 1_
- $a Pomper, Martin G $u The Russell H. Morgan Department of Radiology and Radiological Science , The Johns Hopkins University School of Medicine , 720 Rutland Avenue , Baltimore , Maryland 21205 , United States. The James Buchanan Brady Urologic Institute and Department of Urology , Johns Hopkins School of Medicine , 600 N. Wolfe St. , Baltimore , Maryland 21287 , United States. Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center , The Johns Hopkins University School of Medicine , 401 N. Broadway , Baltimore , Maryland 21231 , United States.
- 700 1_
- $a Artemov, Dmitri $u The Russell H. Morgan Department of Radiology and Radiological Science , The Johns Hopkins University School of Medicine , 720 Rutland Avenue , Baltimore , Maryland 21205 , United States. Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center , The Johns Hopkins University School of Medicine , 401 N. Broadway , Baltimore , Maryland 21231 , United States.
- 773 0_
- $w MED00008279 $t Molecular pharmaceutics $x 1543-8392 $g Roč. 17, č. 1 (2020), s. 98-108
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31840521 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20210105 $b ABA008
- 991 __
- $a 20210114154444 $b ABA008
- 999 __
- $a ok $b bmc $g 1608950 $s 1119795
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 17 $c 1 $d 98-108 $e 20191216 $i 1543-8392 $m Molecular pharmaceutics $n Mol Pharm $x MED00008279
- GRA __
- $a R01 CA209884 $p NCI NIH HHS $2 United States
- LZP __
- $a Pubmed-20210105